Preclinical Neuropathic Pain Assessment; the Importance of Translatability and Bidirectional Research
For patients suffering with chronic neuropathic pain the need for suitable novel therapies is imperative. Over recent years a contributing factor for the lack of development of new analgesics for neuropathic pain has been the mismatch of primary neuropathic pain assessment endpoints in preclinical v...
Main Authors: | Amy S. Fisher, Michael T. Lanigan, Neil Upton, Lisa A. Lione |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-02-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2020.614990/full |
Similar Items
-
Editorial: Translational research in neuropathic pain: Current status and future directions
by: Jay Karri, et al.
Published: (2022-09-01) -
Bridging the translational gap: adenosine as a modulator of neuropathic pain in preclinical models and humans
by: Arendt-Nielsen Lars, et al.
Published: (2023-12-01) -
Comparison of burrowing and stimuli-evoked pain behaviors as end-points in rat models of inflammatory pain and peripheral neuropathic pain
by: Arjun eMuralidharan, et al.
Published: (2016-05-01) -
Editorial: Translational research on neuropathic pain and headache
by: Bamidele Victor Owoyele, et al.
Published: (2022-09-01) -
Preclinical research in paclitaxel-induced neuropathic pain: a systematic review
by: Carolina Bacalhau, et al.
Published: (2023-12-01)